Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Theralase closes $1.2M private placement

Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has closed a non-brokered private placement, issuing 6,666,670 units at C$0.18 per unit, totaling approximately $1.2 million.

Each unit includes one common share and one warrant. The warrants allow purchase of additional shares at $0.25 per share for five years. Proceeds will support Phase II NMIBC clinical study, Rutherrin development, and general corporate purposes.

The company paid a broker's fee of $1,500 and issued 4,166 non-transferrable broker warrants.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK